[HTML][HTML] Spectrum of atazanavir-selected protease inhibitor-resistance mutations
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - Pathogens, 2022 - mdpi.com
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
Spectrum of atazanavir-selected protease inhibitor-resistance mutations.
SY Rhee, M Boehm, O Tarasova, G di Teodoro… - 2022 - cabidigitallibrary.org
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
Spectrum of Atazanavir‐Selected Protease Inhibitor‐Resistance Mutations
SY Rhee, M Boehm, O Tarasova… - Current Research on …, 2022 - iris.uniroma1.it
Ritonavir‐boosted atazanavir is an option for second‐line therapy in low‐and middle-
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - …, 2022 - kups.ub.uni-koeln.de
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - …, 2022 - search.proquest.com
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
Spectrum of Atazanavir‐Selected Protease Inhibitor‐Resistance Mutations
SY Rhee, AJ Bailey, RW Shafer, M Boehm, O Tarasova… - Pathogens, 2022 - elibrary.ru
Ritonavir‐boosted atazanavir is an option for second‐line therapy in low‐and middle-
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
Spectrum of Atazanavir‐Selected Protease Inhibitor‐Resistance Mutations
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - …, 2022 - usiena-air.unisi.it
Ritonavir‐boosted atazanavir is an option for second‐line therapy in low‐and middle-
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
income countries (LMICs). We analyzed publicly available HIV‐1 protease sequences from …
Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations.
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - …, 2022 - search.ebscohost.com
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations.
SY Rhee, M Boehm, O Tarasova… - Pathogens (Basel …, 2022 - europepmc.org
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
[PDF][PDF] Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. Pathogens 2022, 11, 546
SY Rhee, M Boehm, O Tarasova, G Di Teodoro… - 2022 - hivdb.stanford.edu
Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middleincome
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …